March 31 (Reuters) - AzurRx BioPharma Inc :
* AZURRX BIOPHARMA PROVIDES KEY TAKEAWAYS FROM PHASE 2B OPTION 2 CLINICAL TRIAL TOPLINE RESULTS CONFERENCE CALL
* AZURRX BIOPHARMA INC - OPTION 2 TOPLINE RESULTS IS MIXED
* AZURRX BIOPHARMA INC - MS1819 DEMONSTRATED ITSELF TO BE SAFE AND WELL-TOLERATED AND DATA FROM OPTION 2, AND OTHER PHASE 2 CLINICAL TRIALS, CLEARLY DEMONSTRATE DRUG ACTIVITY
* AZURRX BIOPHARMA INC - OPTION 2 DID NOT CONSISTENTLY MEET PRIMARY EFFICACY ENDPOINT.
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.